
ARCA Biopharma Inc
NASDAQ:ABIO

Fundamental Analysis

ARCA Biopharma’s lead candidate Gencaro remains highly dependent on regulatory success in challenging late-stage trials for atrial fibrillation and heart failure, creating vulnerability to pipeline setbacks that could sharply diminish the company’s valuation.
If Gencaro successfully clears regulatory hurdles for atrial fibrillation in heart failure patients, ARCA Biopharma would command a first-mover advantage in a specialized genetic subset, offering significant pricing power and revenue potential.

Revenue & Expenses Breakdown
ARCA Biopharma Inc
Balance Sheet Decomposition
ARCA Biopharma Inc
Current Assets | 33.8m |
Cash & Short-Term Investments | 33.3m |
Other Current Assets | 537k |
Non-Current Assets | 24k |
PP&E | 12k |
Other Non-Current Assets | 12k |
Free Cash Flow Analysis
ARCA Biopharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
ARCA Biopharma Inc
Revenue
|
0
USD
|
Operating Expenses
|
-9.1m
USD
|
Operating Income
|
-9.1m
USD
|
Other Expenses
|
1.9m
USD
|
Net Income
|
-7.2m
USD
|
ABIO Profitability Score
Profitability Due Diligence
ARCA Biopharma Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Score
ARCA Biopharma Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
ABIO Solvency Score
Solvency Due Diligence
ARCA Biopharma Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Score
ARCA Biopharma Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABIO Price Targets Summary
ARCA Biopharma Inc
Dividends
Current shareholder yield for ABIO is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?